Marker Therapeutics, Inc. — Director's Dealing 2011

Apr 5, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2011-03-23

Reporting Person: WILSON GLYNN (Director, Chairman and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-03-23	Common Stock	J	147059	$0.17	Acquired	1047059	Direct

Footnotes

F1: These shares were issued in lieu of $25,000 worth of accrued and unpaid salary.